| Literature DB >> 32351556 |
Fifonsi A Gbeasor-Komlanvi1,2, Wendpouiré I C Zida-Compaore2, Ikpindi H Dare1, Aboudoulatif Diallo1, Tchin P Darre1, Yao Potchoo1, Mofou Belo1, Didier K Ekouevi1,2.
Abstract
BACKGROUND: In the sub-Saharan African, region of the world with a fast growing aging population and where the use of herbal products is very common, there is a paucity of data on medication consumption patterns among elderly people. The objective of this study was to assess the prevalence of polypharmacy and its associated factors among community-dwelling elderly in Lomé, Togo, in 2017.Entities:
Year: 2020 PMID: 32351556 PMCID: PMC7178761 DOI: 10.1155/2020/4346035
Source DB: PubMed Journal: Curr Gerontol Geriatr Res ISSN: 1687-7063
Socio-demographic and clinical characteristics of community-dwelling elderly in Lomé, Togo in 2017 (N = 370).
| Total ( | Male ( | Female ( |
| |
|---|---|---|---|---|
|
| ||||
| Median (IQR) | 65 (62–71) | 66 (63–69.5) | 65 (62–73) | 0.537∗ |
|
| ||||
|
| <0.001∗∗ | |||
| Single | 9 (2.4) | 4 (2.4) | 5 (2.5) | |
| Widowed | 131 (35.4) | 20 (12.0) | 111 (54.6) | |
| Married/living with a partner | 214 (57.8) | 134 (80.2) | 80 (39.4) | |
| Divorced | 15 (4.1) | 9 (5.4) | 6 (3.0) | |
| MD | 1 (0.3) | 0 (0.0) | 1 (0.5) | |
|
| ||||
|
| <0.001∗∗ | |||
| None | 100 (27.0) | 17 (10.2) | 83 (40.9) | |
| Primary school | 107 (29.0) | 42 (25.2) | 65 (32.0) | |
| Secondary school | 100 (27.0) | 60 (35.9) | 40 (19.7) | |
| University | 60 (16.2) | 47 (28.1) | 13 (6.4) | |
| MD | 3 (0.8) | 1 (0.6) | 2 (1.0) | |
|
| ||||
|
| <0.001∗∗∗ | |||
| <150 | 258 (69.7) | 94 (56.3) | 164 (80.8) | |
| (150–450) | 77 (20.8) | 55 (32.9) | 22 (10.8) | |
| >450 | 20 (5.4) | 12 (7.2) | 8 (4.0) | |
| MD | 15 (4.1) | 6 (3.6) | 9 (4.4) | |
|
| ||||
|
| ||||
| Hypertension | 187 (50.5) | 67 (40.1) | 120 (59.1) | <0.001∗∗∗ |
| Diabetes | 67 (18.1) | 30 (17.9) | 37 (18.2) | 0.948∗∗∗ |
| Other CVD1 | 50 (13.5) | 22 (13.2) | 28 (13.8) | 0.862∗∗∗ |
| Osteoarthritis | 219 (59.2) | 84 (50.3) | 135 (66.5) | 0.002∗∗∗ |
| Visual impairment2 | 46 (12.4) | 20 (12.0) | 26 (12.8) | 0.809∗∗∗ |
| Gastrointestinal disease3 | 32 (8.7) | 18 (10.8) | 14 (6.9) | 0.186∗∗∗ |
| Dyslipidemia | 42 (11.4) | 15 (8.9) | 27 (13.3) | 0.192∗∗∗ |
|
| ||||
|
| 0.033∗∗∗ | |||
| 0 | 45 (12.2) | 28 (16.8) | 17 (8.4) | |
| 1 | 112 (30.3) | 54 (32.3) | 58 (28.6) | |
| 2 | 123 (33.2) | 52 (31.1) | 71 (35.0) | |
| ≥3 | 90 (24.3) | 33 (19.8) | 47 (28.0) | |
IQR=interquartile range, MD=Missing data. 1Other CVD= cardiovascular diseases including arrhythmia, cardiac conduction disorders, chronic congestive heart failure. 2Visual impairment including age-related degeneration, cataract, glaucoma, and blindness. 3Gastrointestinal diseases including peptic ulcer, hemorrhoids, chronic constipation, and chronic hepatitis. ∗Mann-Whitney U test; ∗∗Fisher's exact test; ∗∗∗Chi square test.
Medications consumption patterns of community-dwelling elderly in Lomé, Togo in 2017 (N = 370).
| Total ( | Male ( | Female ( |
| |
|---|---|---|---|---|
|
| 0.074∗ | |||
| Median (IQR) | 2 (1–4) | 2 (1–4) | 3 (1–5) | |
|
| ||||
|
| 0.197∗∗ | |||
| 0 | 69 (18.6) | 37 (22.2) | 32 (15.8) | |
| 1 | 51 (13.8) | 21 (12.6) | 30 (14.8) | |
| 2 | 69 (18.6) | 36 (21.5) | 33 (16.2) | |
| ≥3 | 179 (48.4) | 72 (43.1) | 107 (52.7) | |
| MD | 2 (0.6) | 1 (0.6) | 1 (0.5) | |
|
| ||||
|
| ||||
| Conventional drug | 290 (78.4) | 127 (76.1) | 163 (80.3) | 0.083∗∗∗ |
| Dietary supplement | 35 (9.5) | 16 (9.6) | 19 (9.4) | 0.124∗∗∗ |
| Plants/Herbs | 53 (14.3) | 24 (14.4) | 29 (14.3) | 0.983∗∗∗ |
|
| ||||
|
| 0.518∗∗ | |||
| Yes | 249 (67.3) | 116 (69.5) | 133 (65.5) | |
| No | 112 (30.3) | 46 (27.6) | 66 (32.5) | |
| MD | 9 (2.4) | 5 (2.9) | 4 (2.0) | |
|
| ||||
|
| ||||
| Yes | 63 (17.0) | 29 (17.4) | 34 (16.7) | 0.940∗∗ |
| No | 306 (82.7) | 138 (82.6) | 168 (82.8) | |
| MD | 1 (0.3) | 0 (0.0) | 1 (0.5) | |
IQR = interquartile range; MD = Missing data. 1Number of medications including medicinal herbs and dietary supplements. ∗Mann-Whitney U test; ∗∗Fisher's exact test; ∗∗∗Chi square test.
Figure 1Types of medications used according to medical conditions. CVD: Other cardiovascular diseases.
Polypharmacy among community-dwelling elderly in Lomé, Togo in 2017.
| Polypharmacy 1∗ | Polypharmacy 2∗∗ | |||||
|---|---|---|---|---|---|---|
|
| % |
|
| % |
| |
|
| 63/369 | 17.1 | 84/368 | 22.8 | ||
|
| 0.210 | 0.049 | ||||
| Male | 24/167 | 14.4 | 30/166 | 18.1 | ||
| Female | 39/202 | 19.3 | 54/202 | 26.7 | ||
|
| ||||||
|
| 0.434 | 0.906 | ||||
| ≤65 years | 23/151 | 15.2 | 34/151 | 22.5 | ||
| >65 years | 40/218 | 18.3 | 50/217 | 23.0 | ||
|
| ||||||
|
| 0.477 | 0.895 | ||||
| Married/Living with a partner | 39/213 | 18.3 | 48/212 | 22.6 | ||
| Living alone | 24/155 | 15.4 | 36/155 | 23.2 | ||
|
| ||||||
|
| 0.05 | 0.325 | ||||
| None | 10/99 | 10.1 | 17/99 | 17.2 | ||
| Primary school | 18/107 | 16.8 | 25/107 | 23.4 | ||
| Secondary school | 25/100 | 25.0 | 28/99 | 28.3 | ||
| University | 10/60 | 16.7 | 14/60 | 23.3 | ||
|
| ||||||
|
| 0.188 | 0.654 | ||||
| <150€ | 39/257 | 15.2 | 55/256 | 21.5 | ||
| (150–450) | 15/77 | 19.5 | 16/77 | 20.8 | ||
| >450€ | 6/20 | 30.0 | 6/20 | 30.0 | ||
|
| ||||||
|
| ||||||
| Hypertension | 43/187 | 23.0 | 0.002 | 50/186 | 26.9 | 0.061 |
| Other CVD | 21/50 | 42.0 | <0.001 | 26/50 | 52.0 | <0.001 |
| Diabetes | 19/67 | 28.4 | 0.007 | 22/66 | 33.3 | 0.025 |
| Osteoarthritis | 49/218 | 22.5 | 0.001 | 61/217 | 28.1 | 0.004 |
| Visual impairment | 19/46 | 41.3 | <0.001 | 21/46 | 45.7 | <0.001 |
| Dyslipidemia | 17/42 | 40.5 | <0.001 | 19/42 | 45.2 | <0.001 |
|
| ||||||
|
| 58/213 | 27.2 | <0.001 | 70/212 | 33.0 | <0.001 |
∗Polypharmacy 1: number of medications ≥5, not including medicinal plants and other dietary supplements. ∗∗Polypharmacy 2: number of medications ≥5, including medicinal plants and other dietary supplements. CVD = cardiovascular disease.
Multivariable analysis: factors associated with polypharmacy among community-dwelling elderly in Lomé, Togo, 2017.
| Polypharmacy 1∗ | Polypharmacy 2∗∗ | |||||
|---|---|---|---|---|---|---|
|
| aOR (95% CI) |
|
| aOR (95% CI) |
| |
|
| 0.076 | 0.049 | ||||
| Male | 24/167 | 30/166 | 1 | |||
| Female | 39/202 | 54/202 | 1.86 [1.00–3.47] | |||
|
| ||||||
|
| 0.279 | 0.847 | ||||
| ≤65 years | 23/151 | 34/151 | ||||
| >65 years | 40/218 | 50/217 | ||||
|
| ||||||
|
| 0.146 | |||||
| Married/Living with a partner | 39/213 | 48/212 | ||||
| Living alone | 24/155 | 36/155 | ||||
|
| ||||||
|
| 0.092 | 0.182 | ||||
| ≤Primary | 28/206 | 42/206 | ||||
| >Primary | 35/160 | 42/159 | ||||
|
| ||||||
|
| <0.001 | <0.001 | ||||
| No | 5/156 | 1 | 14/156 | 1 | ||
| Yes | 58/213 | 10.27 [3.97–26.57] | 70/212 | 4.55 [2.42–8.54] | ||
∗Polypharmacy 1: number of medications ≥5, not including medicinal plants and other dietary supplements. ∗∗Polypharmacy 2: number of medications ≥5, including medicinal plants and other dietary supplements. 95% CI: 95% confidence interval; aOR: adjusted Odds Ratio.